GenomeFi
GENO - # 698 DelistedKorean Asset
-
Rating Score 20.79Rating Grade D-
- Rating Version APYWA-v1.1 / Rating Date 2025-12-22
Overview
GenomeFi (GENO) is a Web3-focused platform that uses AI and genetics-based NFTs to provide identity verification services reflecting an individual’s genetic traits. Positioned as an AI-powered Web3 Genome DID platform, it aims to develop and mainstream genomics, genetics, biomedicine, and related scientific fields within the blockchain and Web3 ecosystem. GENO is used as the core ecosystem currency and for governance, with plans to further expand its utility to use cases such as GenoPad participation and staking.
Metric Radar Chart
Metric Bar Chart
Metric Trends
| Total Rating Score | TNNeutral |
|---|---|
| Market Accessibility | TNNeutral |
| Development Activity | TNNeutral |
| Market Liquidity | TNNeutral |
| Community Engagement | TNNeutral |
| Risk & Security | TNNeutral |
Total Rating Score Trend
Market Data
- Token Price $0.000000 (-)
- Volume (24h) $- (-)
- Market Cap $- (-)
-
Circulating Supply
40,000,000 GENO
0 GENO
(Source : Coinmarketcap , Coingecko )
Listed Exchanges
- Korean
-
- Global
×
View All Exchanges
- Korean
-
- Global
Community Info
X (Twitter) Tweets (Last 30 Days)
- (-)
Development Info
- GitHub Account -
-
Stars
- (-)
- Commits (Last 3 Months) - (-)
Security Audit Info
- Security Audit Status CertiK
- CertiK Code Security Score 70 pts
(Source : Coinmarketcap , CertiK Skynet )
Issue Info
- Trading History
- 2025.08.04 [고팍스] 거래소에서 거래지원 종료되었습니다. 출금지원 종료 일정: 2025년 9월 4일(목)
- 2025.07.03 [고팍스] 거래소에서 거래지원 종료 공지되었습니다. 거래지원 종료 일정: 2025년 08월 4일(월)
- 2025.04.01 [고팍스] 거래소에서 유의종목 지정되었습니다.
- Risk History
- No records found
View Full History
| Category | Date | Exchange | Link | Grade | Details |
|---|---|---|---|---|---|
| Regular Evaluation | 2024-12-12 | - | - | C-(42.48) | [AW-0012-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-09 | - | - | C-(41.61) | [AW-0011-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-05 | - | - | C-(40.77) | [AW-0010-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-02 | - | - | D(39.37) | [AW-0009-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-11-28 | - | - | D(39.97) | [AW-0008-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-11-25 | - | - | D(38.68) | [AW-0007-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-11-18 | - | - | D(38.68) | [AW-0006-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-11-11 | - | - | D(39.16) | [AW-0005-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-11-04 | - | - | D(39.74) | [AW-0004-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-11-01 | - | - | D(39.29) | [AW-0003-정기] 평가가 완료되었습니다. |
- Disclaimer
-
The ratings provided by APYWA (hereinafter 'the Company') are conducted via an automated system based on public data and are pure data-driven analysis results with no subjective elements. This rating material includes evaluations on five key metrics: Market Accessibility, Development Activity, Market Liquidity, Community Engagement, and Security. All information provided is for reference purposes only.
Our ratings are not intended as investment advice or recommendations, and we do not guarantee the accuracy, completeness, or timeliness of the information. Users must make their own investment decisions based on the provided data, and the Company bears no legal liability for any resulting losses or damages.
While the rating material is processed automatically based on reliable data, discrepancies with actual market conditions may occur due to data limitations. Therefore, the Company is not liable for any damages arising from the use of the provided information. All information contained herein is the property of the Company and may not be reproduced, distributed, or modified without prior approval.